By Marc Gilman

(800) 927-9326 |

If you’re one of the many Medicare beneficiaries who has looked into GLP-1 weight management medications and been discouraged by the cost or the paperwork, there’s a new option worth knowing about. As of this month, Amazon Pharmacy is delivering GLP-1 medications directly to eligible Medicare patients for $50 a month, with the pharmacy handling most of the administrative legwork itself.

Key Takeaways

• Starting July 1, 2026, eligible Medicare Part D patients can get Wegovy (injectable and pill form), Zepbound KwikPen, or Foundayo through Amazon Pharmacy for a flat $50/month, with free home delivery. The program runs through December 31, 2027.

• Ozempic and Mounjaro are not included — only Wegovy, Zepbound KwikPen, and Foundayo qualify, and only for weight loss use.

• You’re not eligible if you have a diagnosis — Type 2 diabetes, heart disease, sleep apnea, or liver disease, for example — that would make your GLP-1 coverable under your existing Part D plan, even if your plan didn’t actually cover it in practice.

• The $50 is a flat Bridge program price, separate from your regular Part D plan — it doesn’t count toward your deductible or annual out-of-pocket maximum.

• Only 28- or 30-day supplies are covered; 90-day supplies and pen needles are not included under the Bridge program.

• A prior authorization from your provider is required on your first fill (typically decided within 72 hours), and switching medications requires a new one — dose changes within the same drug do not.

What Is the Medicare GLP-1 Bridge Program?

The Bridge Program is a temporary program from the Centers for Medicare & Medicaid Services (CMS) that started July 1, 2026, letting eligible Medicare Part D members get certain weight loss medications for a flat $50/month. It runs through December 31, 2027. This is the piece that made Amazon’s $50/month pricing possible in the first place — without the Bridge Program’s cost structure behind it, GLP-1 medications like these typically carry a much higher price tag out of pocket.

Am I Actually Eligible for the Bridge Program?

This is where it’s easy to get tripped up, because eligibility is narrower than “I’m on Medicare and want a GLP-1.” A few things determine whether Bridge applies to you:

• It’s for weight loss use only. If you have a diagnosis — Type 2 diabetes, heart disease, sleep apnea, or liver disease, for example — that would make a GLP-1 coverable under your existing Part D plan, you’re not eligible for Bridge, even if your plan didn’t actually cover it in practice. Bridge fills the gap for weight-loss-only use, not gaps in your existing plan’s coverage.

• A higher copay on your current plan doesn’t make you eligible. If your Part D plan already covers your GLP-1, you can’t switch to the $50 Bridge price just because your copay is higher than that.

• Only three medications qualify: Wegovy, Zepbound KwikPen, and Foundayo. Ozempic and Mounjaro are explicitly not included in the Bridge Program.

• Only 28- or 30-day supplies are covered — 90-day supplies and pen needles aren’t available under this program.

• A prior authorization is required on your first fill, typically decided within 72 hours. Switching from one covered medication to another (say, Wegovy to Zepbound) requires a new PA; adjusting your dose within the same medication does not.

• The $50 doesn’t touch your deductible or out-of-pocket maximum. Bridge runs separately from your regular Part D benefit structure.

What Does Amazon Pharmacy Actually Do Differently Here?

The medication cost was only half the barrier for a lot of patients — the other half has historically been the paperwork: prior authorization delays, benefit verification, and long waits at the pharmacy counter. Amazon Pharmacy is positioning its role as removing that second barrier specifically. Once a clinician sends an electronic GLP-1 prescription to Amazon Pharmacy, the patient adds their Bridge insurance plan and Medicare details to their Amazon Pharmacy account, and Amazon says it handles eligibility verification, prior authorization, and starting the enrollment process from there. According to Amazon Pharmacy vice president and general manager Tanvi Patel, the goal is that once a prescription is sent, nothing else stands between the patient and their medication arriving at their door.

Which Medications Are Included, and How Do You Get Them?

Three GLP-1 medications are currently available through this program, from two manufacturers: Novo Nordisk’s Wegovy (semaglutide), in both injectable and oral pill form, and Eli Lilly’s Zepbound KwikPen (tirzepatide) and Foundayo (orforglipron) pills. All three cost $50 a month with free home delivery under the Bridge Program pricing. Patients have several ways to receive them:

• Free home delivery, available nationwide

• Same-Day Delivery, currently live in more than 3,100 U.S. cities and towns and expanding

• In-office kiosk pickup at select Amazon One Medical locations, where the newly approved Wegovy and Foundayo oral pills are also dispensed

• 24/7 access to licensed pharmacists for questions

• Caregiver support, letting a trusted person manage medications on a loved one’s behalf through their own Amazon account

This all runs through a newly introduced Amazon One Medical weight management program, which combines primary care, pharmacy, and virtual care in one place to treat obesity as an ongoing condition rather than a one-time prescription.

Does This Replace the Need to Understand Your Part D Coverage?

No. Amazon Pharmacy is a delivery and fulfillment option layered on top of the Bridge Program — it doesn’t change the eligibility rules above, and it isn’t a substitute for knowing what your specific Part D plan does and doesn’t cover. If you’re unsure whether you qualify for Bridge versus already having GLP-1 coverage through your existing plan, that distinction is worth sorting out before your provider submits a prescription.

Is This the Same as Amazon’s Other Weight Loss Program?

Not quite, and it’s an easy mix-up. Separate from the Bridge Program, Amazon One Medical also runs a broader weight loss service where you can pay cash for a provider visit and, if eligible, get a GLP-1 prescription with manufacturer coupon savings applied. That cash-pay coupon program explicitly excludes anyone eligible for a state or federal healthcare benefit — including Medicare, Medicare Part D, or Medigap. In other words, if you’re on Medicare, the manufacturer coupons on Amazon’s general weight-loss page aren’t available to you; the Bridge Program described above is the relevant path instead. If you land on Amazon’s general weight-loss service page while searching, don’t assume its cash-pay pricing applies to your situation as a Medicare beneficiary.

Where Does Insurance Planning Fit In?

Gilman Agency isn’t affiliated with Amazon Pharmacy, and we don’t dispense or deliver medications — but we do help clients understand how their Part D coverage, formularies, and out-of-pocket costs work, which is exactly the piece that determines whether a program like this actually applies to you. If you’re considering a GLP-1 medication and want to understand how it fits with your current Medicare plan before you get your clinician involved, that’s a conversation we’re glad to have.

What To Do Next

If you think you might be eligible for the Bridge Program and want to explore GLP-1 options through Amazon Pharmacy or elsewhere, start by talking to your clinician about whether you meet the clinical criteria, and check your Part D plan’s specifics so you know what to expect. If you want a second set of eyes on how this fits with your existing coverage, reach out to Gilman Agency.

Call (800) 927-9326, or email to talk through your situation.

By Marc Gilman, Gilman Agency

Sources: Medicare GLP-1 Bridge Program FAQ, Amazon Pharmacy; Weight Loss Care, Amazon One Medical; Amazon Pharmacy now delivers GLP-1 medications to eligible Medicare patients for $50 a month, Amazon News, August 6, 2026; Amazon Pharmacy Launches GLP-1 Delivery Service, Pharmaceutical Executive, August 7, 2026; Amazon to Offer GLP-1 Weight-Loss Drugs to Medicare Part D Patients, The Wall Street Journal, August 6, 2026; CMS Medicare GLP-1 Bridge Program.